超软局部药物的新概念:通过酶诱导的开关使其失活,变成无活性的形状
Gebhard Thoma1, Eric Vangrevelinghe1, Alexandre Luneau1
1Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
ACS medicinal chemistry letters
|June 14, 2023
概括
这项研究引入了局部药物的新设计. 酶解水解通过引起形状变化来禁用Janus激酶 (JAK) 抑制剂,防止其与JAK激酶结合.
科学领域:
- 药用化学 医学化学
- 药物设计 药物设计
- 药理学 药理学是指药理学的学科.
背景情况:
- 超软局部药物为药物输送提供了一种新的方法.
- 简氏激酶 (JAK) 抑制剂是强大的治疗药物.
- 在局部治疗中,控制药物活性在作用部位至关重要.
研究的目的:
- 提出设计超软局部药物的新概念.
- 为了研究泛亚努斯激酶 (JAK) 抑制剂的酶去活化机制.
- 为了证明局部药物的受控释放和无活化.
主要方法:
- 一种强大的泛-JAK抑制剂 (化合物2) 的碳酸原药的设计和合成.
- 在人体血液中进行酶分离研究,以释放活性代谢物 (氧氨酸3).
- 形态分析以确定 tautomerism 对生物活性的影响.
主要成果:
- 碳酸原药的酶性水解 (2) 释放出氧氨酸 (3).
- 氧氨酸 (3) 经历快速的复合 (氧氨酸-氨酸),改变其构造.
- 这种形状变化阻止了与JAK激酶的结合,导致药物失活.
结论:
- 拟议的前药物策略有效地使人类血液中的JAK抑制剂失活.
- 酶性水解与陶托马力诱导的形状变化相结合,是超软局部药物的可行机制.
- 这种方法提供了一种新的方式来控制局部治疗的活性和局部化.
相关概念视频
Prodrugs
2.7K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.7K
Drug Biotransformation: Overview
2.5K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.5K
Principles of Drug Action
6.2K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.2K
Targets for Drug Action: Overview
6.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.5K
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
235
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
235
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.9K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.9K


